BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: le Roux SM, Cotton MF, Golub JE, le Roux DM, Workman L, Zar HJ. Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Med. 2009;7:67. [PMID: 19886982 DOI: 10.1186/1741-7015-7-67] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tolofoudie M, Somboro A, Diarra B, Sarro YS, Drame HB, Togo ACG, Sanogo M, Dembele A, Togun T, Nkereuwem E, Baya B, Konate B, Egere U, Traore M, Maiga M, Saliba-Shaw K, Kampmann B, Diallo S, Doumbia S, Sylla M. Isoniazid preventive therapy in child household contacts of adults with active TB in Bamako, Mali. Public Health Action 2021;11:191-5. [PMID: 34956847 DOI: 10.5588/pha.21.0061] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hunter OF, Kyesi F, Ahluwalia AK, Daffé ZN, Munseri P, von Reyn CF, Adams LV. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania. BMC Infect Dis 2020;20:738. [PMID: 33028260 DOI: 10.1186/s12879-020-05471-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
3 Keating AV, Soto J, Forbes C, Zhao M, Craig DQM, Tuleu C. Multi-Methodological Quantitative Taste Assessment of Anti-Tuberculosis Drugs to Support the Development of Palatable Paediatric Dosage Forms. Pharmaceutics 2020;12:E369. [PMID: 32316692 DOI: 10.3390/pharmaceutics12040369] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Riquelme-Miralles D, Palazón-Bru A, Sepehri A, Gil-Guillén VF. A systematic review of non-pharmacological interventions to improve therapeutic adherence in tuberculosis. Heart Lung 2019;48:452-61. [PMID: 31084923 DOI: 10.1016/j.hrtlng.2019.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Okwara FN, Oyore JP, Were FN, Gwer S. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study. BMC Infect Dis 2017;17:623. [PMID: 28915796 DOI: 10.1186/s12879-017-2719-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
6 Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev 2017;8:CD006418. [PMID: 28850172 DOI: 10.1002/14651858.CD006418.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
7 Egere U, Sillah A, Togun T, Kandeh S, Cole F, Jallow A, Able-Thomas A, Hoelscher M, Heinrich N, Hill PC, Kampmann B. Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia. Public Health Action 2016;6:226-31. [PMID: 28123958 DOI: 10.5588/pha.16.0073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
8 Costenaro P, Massavon W, Lundin R, Nabachwa SM, Fregonese F, Morelli E, Alowo A, Nannyonga Musoke M, Namisi CP, Kizito S, Bilardi D, Mazza A, Cotton MF, Giaquinto C, Penazzato M. Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience. J Acquir Immune Defic Syndr 2016;71:e1-8. [PMID: 26761275 DOI: 10.1097/QAI.0000000000000806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Yotebieng M, Edmonds A, Lelo P, Wenzi LK, Ndjibu PT, Lusiama J, Kabuayi JP, Behets F. High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. AIDS 2015;29:2055-7. [PMID: 26352882 DOI: 10.1097/QAD.0000000000000791] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shivaramakrishna HR, Frederick A, Shazia A, Murali L, Satyanarayana S, Nair SA, Kumar AM, Moonan PK. Isoniazid preventive treatment in children in two districts of South India: does practice follow policy? Int J Tuberc Lung Dis 2014;18:919-24. [PMID: 25199005 DOI: 10.5588/ijtld.14.0072] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
11 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health 2012;17:1264-73. [PMID: 22862994 DOI: 10.1111/j.1365-3156.2012.03053.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
13 Cruz AT, Starke JR. Increasing adherence for latent tuberculosis infection therapy with health department-administered therapy. Pediatr Infect Dis J 2012;31:193-5. [PMID: 21979799 DOI: 10.1097/INF.0b013e318236984f] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
14 Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, Van Crevel R, Alisjahbana B, Hill PC. Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Res Notes 2012;5:7. [PMID: 22221424 DOI: 10.1186/1756-0500-5-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
15 Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database Syst Rev 2011;:CD009513. [PMID: 22161452 DOI: 10.1002/14651858.CD009513] [Cited by in Crossref: 25] [Cited by in F6Publishing: 59] [Article Influence: 2.3] [Reference Citation Analysis]
16 Verhagen LM, Warris A, van Soolingen D, de Groot R, Hermans PW. Human immunodeficiency virus and tuberculosis coinfection in children: challenges in diagnosis and treatment. Pediatr Infect Dis J 2010;29:e63-70. [PMID: 20651637 DOI: 10.1097/INF.0b013e3181ee23ae] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
17 Zar HJ, Workman L, le Roux SM, Jennings T, Jele N, Schaaf HS, Barclay-Loggie A, Mulligan C, le Roux DM, Lombard CJ, Cotton MF; INH study team. A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. AIDS 2010;24:2225-32. [PMID: 20706110 DOI: 10.1097/QAD.0b013e32833d4533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
18 Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist 2010;3:63-72. [PMID: 21694895 DOI: 10.2147/idr.s8994] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]